Follow us

About us

Management

Géraldine Le Duc, PhD

Chief Executive Officer & Co-Founder

  • 30 years of expertise in drugs for radiotherapy and imaging of cancer (Guerbet, INSERM, BNL-USA, ESRF)
  • More than 100 scientific publications, 4 patents
  • Discovery of the radiosensitization effect of AGuIX®
  • PhD in Biomedical Physics
CONTRAST-AGENT2

Markus Loeffler, MD & MBA

Chief Medical Officer

  • More than 20 years of international leadership experience in oncology (Boehringer Ingelheim, Roche, AAA, Mundipharma EDO)
  • Expertise in all stages of research and clinical development from first in human to market
  • MD & MBA from INSEAD

Michel Julien, PhD

CMC Director

  • Over 20 years of experience in parenteral drug research and development
  • Strong expertise in CMC activities from lead candidate selection to manufacturing process validation including management of CMOs
  • PhD in Biochemistry
caroline-cayre

Caroline Cayre

Head of Finance and Administration

  • 25+ years spent in Finance & Business administration, including 15 years in international business environment
  • Broad industry experience: Audit (PwC), Large international groups (HP), Fast growing SMEs/Start-ups (Aledia)
  • French Business School (1995) – Studies abroad (Bath-UK), Certified Coach (Teams & Organizations)

Board of directors

herve-brailly

Géraldine Le Duc

CEO & Co-Founder

herve-brailly

Hervé Brailly

Chairman

olivier-tillement

Olivier Tillement

Scientific Advisor & Co-Founder
AGuIX® Inventor, University Professor

philippe-boucheron

Philippe Boucheron

Life Sciences Investor
Bpifrance

thibaut-roulon

Thibaut Roulon

Life Sciences Investor
Bpifrance

herve-brailly

Nitza Thomasson

Life Sciences Investor
Omnes

marc-lebozec

Marc Lebozec

Life Sciences Investor
Arbevel

marc-lebozec

Célia Hart

Life Sciences Investor
Supernova

yannick-pletan

Yannick Pletan

Formely Country Medical Director
Roche

philippe-archinard

Philippe Archinard

Deputy CEO-Innovation & Scientific Partnerships
Institut Mérieux

Partners